Therapy Areas: Oncology
Reaction Biology to acquire Bioassay Labor fur biologische Analytik GmbH and its wholly-owned subsidiary
5 December 2022 -

Reaction Biology Corporation, a US-based provider of drug discovery and development services, announced on Friday that it has entered into a definitive agreement to acquire Bioassay Labor fur biologische Analytik GmbH (Bioassay), including its wholly-owned subsidiary, Peptide Specialty Laboratories GmbH (PSL), located in Heidelberg, Germany.

Bioassay offers Good Manufacturing Practices (GMP) accredited potency assays and functional bioassays, Good Laboratory Practices (GLP) compliant services, and through PSL, peptide synthesis services, including peptide-specific antibody production and neoantigen synthesis. Reaction said that personnel, equipment, and facilities from the acquired companies will expand its presence in Germany, while also enabling its global customers to leverage Bioassay's expansive portfolio of regulated clinical and commercial services.

Reaction's legal counsel for the deal is White & Case LLP while Bioassay GmbH's financial advisor and legal counsel were ACXIT Capital Partners, a Stifel Company, and Goodwin Procter LLP respectively.

John H Johnson, Reaction Biology chief executive officer, said, 'Market demand is increasing globally for large molecule services as biopharmaceutical companies search for new treatment options for patients suffering with cancer and other serious diseases. This transaction enables Reaction Biology to add Bioassay GmbH's impressive clinical phase and post-approval infrastructure, which includes large molecule capabilities, as well as its GMP and GLP accreditations, to our expanding suite of drug discovery and development services. We can now provide our customers with even broader offerings to meet their research and development goals.'